Europe Strengthens Collaborations with Japanese Pharmacopoeia
EDQM and the Japanese Pharmacopoeia will improve the sharing of information on therapeutic products that are common in both Europe and Japan.
On Oct. 3, 2016, the European Directorate for the Quality of Medicines & HealthCare (EDQM) announced an enhanced collaboration between the directorate, the Pharmaceutical Safety and Environmental Health Bureau of the Ministry of Health, Labour and Welfare (MHLW), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. The agencies will share information regarding GMP inspections of API manufacturing sites of interest to both Europe and Japan.
EDQM also signed a five-year Memorandum of Cooperation defining measures for strengthening collaboration between the European and Japanese pharmacopoeias, which include bilateral meetings, workshops, and internships between the two pharmacopoeias and various Japanese regulatory bodies. An ad hoc Technical Working Group on relevant topics was also agreed upon.
“This strengthened relationship will enhance the ability of the MHLW, PMDA, and EDQM to protect and promote the health and safety of the populations of their respective country/region. The constant aim of the partners will be to facilitate increased access to safe, effective, and high-quality products in Europe and Japan,” EDQM stated in a press release.
Source: EDQM
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
